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Abstract
Neurotrophins protect neurons against glutamate excitotoxi-
city, but the signaling mechanisms have not been fully
elucidated. We studied the role of the phosphatidylinositol
3-kinase (PI3-K) and Ras/mitogen-activated protein kinase
(MAPK) pathways in the protection of cultured hippocampal
neurons from glutamate induced apoptotic cell death,
characterized by nuclear condensation and activation of
caspase-3-like enzymes. Pre-incubation with the neurotrophin
brain-derived neurotrophic factor (BDNF), for 24 h, reduced
glutamate-evoked apoptotic morphology and caspase-3-like
activity, and transiently increased the activity of the PI3-K and
of the Ras/MAPK pathways. Inhibition of the PI3-K and of the
Ras/MAPK signaling pathways abrogated the protective effect
of BDNF against glutamate-induced neuronal death and
similar effects were observed upon inhibition of protein
synthesis. Moreover, incubation of hippocampal neurons with
BDNF, for 24 h, increased Bcl-2 protein levels. The results
indicate that the protective effect of BDNF in hippocampal
neurons against glutamate toxicity is mediated by the PI3-K
and the Ras/MAPK signaling pathways, and involves a long-
term change in protein synthesis.
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Introduction
Neurotrophins play an important role in the development of
the nervous system, by influencing cell survival, differentiation
and cell death.1 Furthermore, gradients of neurotrophins are
able to steer growth cones in vitro, acting as chemoattractants
or chemorepellents, depending on the cyclic nucleotide levels
within the neurons.2,3 In vivo brain-derived neurotrophic factor
(BDNF) has been shown to rescue different types of neurons
from ischemic, traumatic and toxic brain injury.4–10 Blocking
endogenous BDNF activity leads to aggravated death of a
subpopulation of hippocampal neurons after global forebrain
ischemia.11 The neuroprotective role of endogenous BDNF is
further supported by the observed correlation between BDNF
protein levels and resistance to ischemic damage in the
various hippocampal subregions.12 Furthermore, intravenous
administration of BDNF 30 min after middle cerebral artery
occlusion reduced infarct size in the cerebral cortex and
counter-regulated Bcl-2 and Bax expression.8 Intraventricular
injection of BDNF also increased survival of rat hippocampal
CA1 pyramidal neurons following transient forebrain ischemia.4
In addition to the long-term effects, neurotrophins also exhibit
acute effects on neurotransmitter release, synaptic strength
and connectivity.13,14
The cellular actions of neurotrophins are mediated through
the activation of the Trk family of receptors, TrkA-C, and the
p75 neurotrophin receptor. The latter receptor binds to all
neurotrophins with a similar affinity, whereas the TrkA, TrkB
and TrkC receptors are activated preferentially by nerve
growth factor (NGF), BDNF and neurotrophin-3 (NT-3),
respectively.14 Once activated, the Trk receptors autophos-
phorylate specific tyrosine residues, which serve as interac-
tion sites for proteins endowed with PTB/SH2 domains. The
consequences of Trk receptor activation include the activation
of Ras, mediated by the adapter proteins Shc/Grb2/SOS,
leading to the activation of extracellular signal-regulated
kinases (ERK), members of the mitogen-activated protein
kinase (MAPK) family, and of phospholipase C-g and
phosphatidylinositol 3-kinase (PI3-K). Phospholipase C-g
generates diacylglycerol and inositol 1,4,5-trisphosphate,
and PI3-K forms 30-phosphorylated phosphoinositides, which
allow the activation of pH-containing proteins, including
Akt/PKB.1 Activation of Akt has acute effects on cell survival,
due to phosphorylation of Bad, which in the phosphorylated
form is sequestered in the cytosol by 14-3-3, precluding its
proapoptotic effects on the mitochondria.15 Furthermore,
active ERKs and Akt are translocated to the nucleus where
they can phosphorylate certain transcription factors, thereby
regulating the expression of specific genes that contribute to
cell survival.1,16
Neurotrophins were shown to protect cultured hippocampal
neurons from glutamate-evoked cell death, by upregulating
the antioxidant defense system.17 During overstimulation of
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glutamate receptors, the mitochondria become de-energized
and produce reactive oxygen species due to the accumulation
of large amounts of Ca2þ .18–21 It has been proposed that the
ability of mitochondria to recover their energetics after a
glutamate insult determines the mode of cell death, by
apoptosis or by necrosis.18 Neuronal death by apoptosis is
characterized by the release of cytochrome c, which allows
the activation of caspase-9. This caspase acts upstream of
caspase-3, the major executioner caspase in neurons.22–25
Although neurotrophins protect hippocampal neurons in vivo
and in vitro, the signaling mechanisms responsible for this
protection are still not fully understood. In the present work, we
determined the role of the PI3-K pathway and of the Ras/ERK
pathway in neuroprotection by BDNF from glutamate toxicity.
The results show that BDNF protects hippocampal neurons at
the level or upstream of the activation of caspase-3-like
enzymes, by a mechanism involving both signaling pathways.
Results
BDNF protects cultured hippocampal neurons
from glutamate-induced cell death
Cultured hippocampal neurons were challenged with 125 mM
glutamate and cell death was accessed by analyzing nuclear
morphology, 7 h after the excitotoxic insult, using the
fluorescent dyes Syto-13 and propidium iodide. After the
excitotoxic insult with glutamate about 40–45% of the cells
displayed an apoptotic morphology (Figure 1), characterized
by chromatin condensation and loss of neurites (not shown).
Pre-incubation of the cells with BDNF (Figure 1b) or NT-3
(Figure 1c), for 24 h, before the glutamate insult, reduced the
number of apoptotic cells in a dose-dependent manner. BDNF
was more efficient in protecting the cells than NT-3 at the
maximal concentration used (200 ng/ml), reducing the toxic
effect of glutamate by about 60%. As expected, NGF (20–
100 ng/ml) did not protect hippocampal neurons from gluta-
mate toxicity, in agreement with the known absence of TrkA
receptors in the preparation.26
Activation of caspase-3 is a hallmark of apoptotic cell death
and precedes changes in nuclear morphology.27 Pre-incuba-
tion of hippocampal neurons with Z-DEVD-FMK, a cell
permeable irreversible inhibitor of caspase-3-like enzymes,28
significantly reduced glutamate-induced cell death
(Figure 2a). However, at the maximal concentration used,
the caspase inhibitor did not fully protect the cells. In control
experiments hippocampal neurons were treated only with the
caspase inhibitor (50–100mM), and no toxicity was observed.
To further confirm that in our model system glutamate
induced an apoptotic-like form of neuronal cell death, we
Figure 1 BDNF and NT-3, but not NGF, protect hippocampal neurons from
glutamate-induced cell death. Hippocampal neurons were treated with NGF (a),
BDNF (b) or NT-3 (c), for 24 h, and then challenged with 125 mM glutamate for
15 min, in fresh Neurobasal medium containing B27 supplement, and then
returned to the original medium. Cell death was accessed 7 h after the insult by
fluorescence microscopy, using the fluorescence dyes Syto-13 and PI. Control
cells were incubated for 15 min, with fresh glutamate-free Neurobasal medium
containing B27 supplement, and were then returned to the original culture
medium. Data are presented as the mean7s.e.m. of the indicated number of
experiments, performed in independent preparations. ***Po0.001 as compared
with control cells; þ þ þPo0.001 as compared with cells stimulated with
glutamate alone
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measured caspase-3-like activity in extracts prepared from
hippocampal cultures treated or not with glutamate, using the
chromogenic substrate Ac-DEVD-pNA. The results show that
excitotoxic stimulation with glutamate increased caspase-3-
like activity, but this effect was not observed in cells pre-
incubated with BDNF for 24 h, before the toxic insult. These
results indicate that BDNF protects hippocampal neurons at
the level or upstream of the activation of caspase-3-like
enzymes.
The Ras/MAPK pathway is involved in
neuroprotection by BDNF against glutamate
toxicity
Since BDNF was more potent in protecting hippocampal
neurons against glutamate toxicity than NT-3, we further
investigated the signaling pathways responsible for the effect
of the former neurotrophin. Activation of Trk receptors by
BDNF was required for neuroprotection, since no effect of the
neurotrophin on glutamate toxicity was observed when the
experiments were conducted in the presence of K252a
(200 nM), an inhibitor of this family of receptors29 (Figure 3a
and b). Control experiments showed that K252a did not affect
glutamate toxicity in the absence of BDNF. The effect of
K252a on Trk receptors was confirmed by Western blot, using
an antibody that recognizes phosphotyrosine 490 in TrkA, a
residue conserved in the other Trk receptors. Stimulation of
cultured hippocampal neurons with 100 ng/ml BDNF, for
5 min, increased Trk (presumably TrkB) phosphorylation,
and this effect was inhibited by K252a (Figure 3c).
The kinetics of activation of the Ras/ERK pathway by BDNF
was followed by Western blot, using an antibody that
specifically recognizes the dually phosphorylated (active)
form ERK1 and 2.30 The activity of ERK 1 and 2 in cultured
hippocampal neurons was very low under resting conditions,
but it was transiently increased upon stimulation of the cells
with 100 ng/ml BDNF. The kinetics of activation of the two
kinases was similar (Figure 4c and d), although the increase in
phospho-ERK2 immunoreactivity was more significant than
that obtained for phospho-ERK1 (Figure 4a). The total amount
of ERK2 present in the cells was also higher than the
expression of ERK1 protein (Figure 4b). The maximal
phosphorylation of ERKs was attained after 7.5–10 min of
stimulation, and the activity of the kinases decreased after-
wards, towards a plateau close to basal levels. After 24 h
stimulation of hippocampal neurons with BDNF, an incubation
period that confers neuroprotection (Figure 1), the phosphory-
lation of ERK1 and 2 was not significantly different from basal
phosphorylation (P40.05).
In order to test if the activation of the ERK pathway was
involved in the neuroprotective effect of BDNF, we inhibited
pharmacologically MAPK/ERK Kinase (MEK), the upstream
kinase of ERK, with PD098059 (20 mM)31 or U0126
(300 nM).32 In the presence of the MEK inhibitors, the
neuroprotective effect of BDNF against glutamate-evoked
cell death was completely abrogated (Figure 5a), as observed
by analysis of nuclear morphology, indicating that the ERK
pathway mediates the neuroprotective effect of BDNF against
glutamate toxicity (Po0.001). When PD098059 and
LY294002, a PI3-K inhibitor, were present together, no
additive effect was observed. Control experiments revealed
that the two MEK inhibitors used were without effect on
glutamate toxicity measured in the absence of BDNF
(Figure 5b). To test for possible toxic effects of those
inhibitors, hippocampal neurons were treated independently
with PD098059 or U0126, at the concentration used in this
work, and no toxicity was observed (not shown).
The concentrations of the MEK inhibitors used in the
present work are below the range of concentrations that fully
block the kinase in in vitro assays.33 However, we could not
use higher concentrations of the antagonists because of their
toxic effects. Since the effect of inhibitors of MEK activation in
vivo may also depend on how potently the signaling pathway
is activated by any particular agonist,31 we determined the
effect of PD098059 and of U0126 on the phosphorylation of
ERK1/2 in hippocampal neurons stimulated with BDNF. The
results of Figure 5c show that PD098059 inhibited the
phosphorylation of ERK1 and 2 in response to stimulation
Figure 2 BDNF inhibits caspase-3-like activity induced by glutamate. (a)
Hippocampal neurons were challenged with 125mM glutamate, for 15 min, in the
presence or absence of the indicated concentrations of the caspase-3 like
inhibitor Z-DEVD-FMK. Control cells were incubated with the inhibitor alone, at
the indicated concentrations, and no toxicity was observed. The experiments
were conducted as described in the caption of Figure 1 and cell death was
assessed 7 h after the insult. (b) Hippocampal neurons were treated or not with
100 ng/ml BNDF, for 24 h, and challenged with 125 mM glutamate or not (control),
for 15 min. Caspase-3-like activity in cellular extracts was assessed 5 h after the
insult by following the cleavage of the Ac-DEVD-pNA substrate. Data are
presented as mean7S.E.M. of the indicated number of experiments, performed
in independent preparations. ***Po0.001 as compared to control; þ þPo0.01,
þ þ þPo0.001 as compared with cells stimulated with glutamate alone
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with 100 ng/ml BDNF by about 65%. U0126 also inhibited the
phosphorylation of ERK1 and 2 by about 60 and 20%,
respectively.
In order to further confirm the role of the ERK pathway in the
neuroprotection by BDNF, we performed experiments trans-
fecting hippocampal neurons with a dominant-negative
construct of MEK (MEK KN).34 When hippocampal neurons
were transfected with the dominant-negative form of MEK, the
neuroprotective effect of BDNF was abolished, in agreement
with the results obtained with the pharmacological inhibitors
(Figure 5d). Control experiments revealed that transfection of
hippocampal neurons with the MEK KN does not affect
glutamate toxicity measured in the absence of BDNF. The
transfection by its own did not induce any toxicity, as well as
the transfection of neurons with GFP plus MEK KN or GFP
alone (data not shown). Taken together, the results indicate
that the ERK pathway mediates the protective effect of BDNF
against excitotoxic insults in cultured hippocampal neurons.
The PI3-K/Akt pathway is involved in BDNF
neuroprotection against glutamate
In order to evaluate the effect of BDNF on the PI3-K pathway
in cultured hippocampal neurons, we determined the kinetics
of phosphorylation of Akt, a kinase that is a downstream
effector of PI3-K. Akt is activated by phosphorylation on
Thr308, Ser473 and on a tyrosine residue, by different
kinases, and phosphorylation of these sites is necessary for
full activation of the kinase.35,36 Therefore, we assessed the
phosphorylation of Akt on Ser473 and on Thr308, by Western
blot, as a measurement of the activity of the PI3-K pathway.
Under resting conditions there was a basal phosphorylation of
Akt on Ser473 (Figure 6b) and on Thr308 (Figure 6c), which
contrasts with the low phosphorylation of ERK1/2 shown in
Figure 4. Upon stimulation of the cells with BDNF, there was a
2.5-fold increase in the phosphorylation of Akt on Thr308 and
a 3.2-fold increase in Ser473 phosphorylation. This increase
in Akt activity was transient, peaking after 7.5–10 min of
stimulation, and decreasing afterwards towards a plateau.
After 24 h stimulation of hippocampal neurons with
BDNF, an incubation period that leads to neuroprotection
against glutamate toxicity (Figure 1), the phosphorylation
of Akt was not significantly different from basal phosphory-
lation (P40.05).
The role of the PI3-K pathway in the protection by BDNF
against glutamate toxicity was investigated using two chemi-
cally different inhibitors of the enzyme: wortmannin, a fungal
toxin that covalently binds to and blocks the activity of the
catalytic p110 subunit of PI3-K,37 and LY294002, a synthetic
bioflavenoid that reversibly binds to and inhibits p110.38 Pre-
incubation of the cells with LY294002 (30 mM) or with
Figure 3 The neuroprotective effect of BDNF is mediated through the
activation of Trk receptors. (a) Hippocampal neurons were pretreated or not with
the Trk inhibitor, K252a (200 nM), 30 min before they were incubated for 6 h, with
100 ng/ml BDNF. This pre-incubation period provides maximal protection by
BDNF (see Figure 10). The cells were then challenged with glutamate (125 mM)
during 20 min. Cell death was accessed 14 h later by fluorescence microscopy,
using the fluorescent dye Hoechst 33342. Data are presented as mean7S.E.M.
of three experiments, performed in independent preparations, and are expressed
as a percentage of cell death observed in response to glutamate stimulation
alone. **Po0.01 as compared with cells stimulated with glutamate alone;
þPo0.05. The nuclear morphology of control cells, and the effect excitotoxic
stimulation with glutamate, in the presence or in the absence of BDNF, are shown
in (b). The inhibition of neuroprotection by BDNF in the presence of K252a is also
shown in (b). (c) Hippocampal neurons were pretreated or not with 200 nM
K252a, for 30 min, and then incubated with 100ng/ml BDNF, for 5 min, with or
without the Trk inhibitor. Cells were then lysed and total extracts (30 mg) were
analysed by Western blot, using an anti-phospho-Trk (phosphotyrosine 490)
antibody. Protein loading was checked by stripping and reprobing the membrane
with an anti-actin antibody. The immunoreactivity obtained in each experimental
condition was calculated as a percentage of the control. The results of a
representative experiment are also shown. Data are presented as mean7
S.E.M. of three different experiments, performed in independent preparations.
***Po0.001 as compared with the control, nonstimulated cells; þ þ þPo0.001
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wortmannin (100 nM), before and during stimulation with
BDNF, significantly inhibited (Po0.001) the protective effect
of the neurotrophin against glutamate-evoked cell death
(Figure 7a). In the presence of BDNF and wortmannin or
LY294002, cell death induced by glutamate was not sig-
nificantly different from that evoked by glutamate alone
(Po0.05). When PI3-K and MEK were simultaneously
inhibited during stimulation of the cells with BDNF, with
LY294002 and PD098059, respectively, the toxic effect of
glutamate was not different from that observed in the
presence of BDNF and with the PI3-K inhibitor alone.
Control experiments revealed that the two PI3-K inhibitors
used were without effect on the toxicity of glutamate
measured in the absence of BDNF (Figure 7b). To test for
possible toxic effects of those inhibitors, hippocampal neurons
were treated with wortmannin and LY294002 alone, at the
concentration used in this work, and no toxicity was observed
(not shown).
In order to confirm that the PI3-K inhibitors used indeed
affect this signaling pathway at the concentration used, we
determined the effect of LY294002 (30mM) and wortmannin
(100 nM) on the phosphorylation of Akt on Ser473, in the
absence and in the presence of BDNF. Akt phosphorylation at
Ser473 was reduced to values below (LY294002) or similar
(wortmannin) to those of basal conditions (Figure 7c), con-
firming that PI3-K pathway was indeed inhibited by the
pharmacological compounds used.
To further confirm the role of PI3-K pathway in the
neuroprotection by BDNF, we performed experiments trans-
fecting hippocampal neurons with a dominant-negative form
of Akt (Akt KN).39 Our results show that BDNF neuroprotec-
tion was completely prevented when the cells were trans-
fected with a dominant-negative form of Akt (Akt KN)
(Figure 7d), confirming the pharmacological data. Control
experiments revealed that transfection of hippocampal
neurons with Akt KN does not affect glutamate toxicity
measured in the absence of BDNF. Neither the transfection
process by its own nor GFP induce any toxicity to the neurons
(data not shown), but the dominant-negative form of Akt
increased basal cell death by about 9%.
PI3-K/Akt cross-talks with Ras/MAPK pathway
Our results showing that inhibition of PI3-K and MEK affects to
the same extent the protection of hippocampal neurons by
BDNF against glutamate toxicity may suggest that: (i) the two
signaling pathways share a common mechanism of neuro-
protection and/or (ii) inhibition of a pathway not involved in
neuroprotection leads to the inhibition of the protective
pathway. The latter hypothesis suggests that there might be
a strong cross-talk between the PI3-K and the MEK pathway.
Accordingly, inhibition of the PI3-K and PDK1 has been shown
to inhibit the ERK pathway in a cell type- and ligand-specific
manner.40–44
In order to determine whether the PI3-K pathway controls
the activation of ERK1/2 in hippocampal neurons exposed to
BDNF, we determined the phosphorylation of the kinase in
cells stimulated with the neurotrophin in the presence or
absence of PI3-K antagonists. The PI3-K inhibitor LY294002
(30 mM) inhibited the phosphorylation of ERK1 and 2 by about
70%, and wortmannin (100 nM) decreased the phosphoryla-
tion of ERK1 and 2 stimulated by BDNF by about 80 and 60%,
respectively (Figure 8). As expected, both PI3-K inhibitors
were without effect on the phosphorylation of ERK1/2 under
resting conditions.
Since the kinetics of activation of the Ras/MAPK pathway
and of the PI3-K pathway in hippocampal neurons stimulated
with BDNF is very similar, we also investigated a putative
effect of MEK on the latter signaling pathway. Inhibition of
Figure 4 BDNF induces a transient activation of ERK1 and ERK2 in cultured
hippocampal neurons. Cellular preparations were treated with 100 ng/ml BDNF
for the indicated time periods and then lysed and analyzed by immunoblot
against P-ERK1 and P-ERK2 (a, c and d). Panel (a) shows the result of a
representative experiment. In each experimental condition the immunoreactivity
obtained was calculated as a percentage of the total signal obtained for the
corresponding isoform. Data are presented as mean7S.E.M. of four
independent experiments. In (b) nonstimulated cultured hippocampal neurons
were lysed and immunobloted using an antibody that recognizes total ERK1/2.
The results are representative of three independent experiments
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MEK with PD098059 or with U0126 during stimulation of
hippocampal neurons with BDNF had a minor effect on the
activation of the PI3-K pathway, as determined by the
phosphorylation of Akt on Ser473. Furthermore, both inhibi-
tors were without effect on the phosphorylation of the kinase
on Ser473 under resting conditions (Figure 8b). Therefore, the
results indicate that the PI3-K pathway contributes to the
activity of the Ras/MAPK pathway in hippocampal neurons
stimulated with BDNF.
BDNF does not downregulate glutamate-evoked
activation of the p38 MAPK and c-Jun N-terminal
kinase (JNK) signaling pathways
Recent studies showed that activation of the p38 MAPK
mediates glutamate-induced apoptotic death of cultured
cerebellar granule neurons.45,46 Excitotoxic stimulation of
glutamate receptors was also shown to activate JNK, and this
pathway may also contribute to cell death.45,47,48 Therefore,
we investigated whether a downregulation of p38 MAPK and/
or JNK signaling pathways could account for neuroprotection
by BDNF. Stimulation of cultured hippocampal neurons with
glutamate induced a transient phosphorylation of p38 MAPK
(Thr180/Tyr182), with a maximal effect at 5 min (not shown).
However, the effect of glutamate was not significantly different
in cells pre-incubated with BDNF for 24 h (Figure 9a). In
addition to p38 MAPK, there was also a transient increase
in the phosphorylation of a JNK isoform (Thr183/Tyr185), with
an apparent molecular mass of 46 kDa, in hippocampal
neurons stimulated with glutamate. The maximal effect was
observed after 5 min of stimulation with glutamate (not
shown), and the phosphorylation (activation) of this JNK
isoform was not affected in cells pre-incubated with BDNF for
24 h (Figure 9b). The antibody used also recognized two other
bands, with a higher apparent molecular mass, whose
immunoreactivity did not change in response to glutamate
stimulation. These results indicate that the protection by
Figure 5 The neuroprotective effect of BDNF is mediated through the Ras/MAPK pathway. Hippocampal neurons were pretreated with the MEK inhibitors, PD098059
(20 mM) and U0126 (300 nM), for 15 min, before they were incubated (a), or not (b), for 24 h, with 100 ng/ml BDNF, and then challenged with glutamate. Cell death was
assessed 7 h later by fluorescence microscopy using the fluorescence dyes Syto-13 and PI. (c) Hippocampal neurons were pretreated with 20 mM PD098059 or 300 nM
U0126, for 15 min, and then incubated with BDNF, for 7.5 min, with or without MEK inhibitors. Cells were lysed and total cell extracts (12.5 mg protein) were analyzed by
Western blot using an anti-phospho-ERK1/2 antibody. Protein loading was checked by stripping and reprobing the membrane with an anti-tubulin (a-tubulin) antibody.
The data are representative of three independent experiments. In (d), hippocampal neurons were co-transfected with a dominant-negative construct of MEK (MEK KN)
and GFP, for 24 h, in a proportion 5 : 1, respectively, and then treated with 100 ng/ml BDNF. After 24 h incubation with BDNF, the cells were challenged with glutamate
and death of GFP-positive neurons was assessed 14 h later by fluorescence microscopy, using the fluorescent dye Hoechst 33342. Data are presented as
mean7S.E.M. of the indicated number of experiments, performed in independent preparations, and are expressed as a percentage of cell death, by apoptosis,
observed in response to glutamate stimulation alone. ***Po0.001 as compared to glutamate-induced cell death
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BDNF under excitotoxic conditions is not due to an effect on
the activation of stress-activated protein kinases.
The neuroprotective effect of BDNF is protein
synthesis dependent
Considering that the BDNF treatment induces a rapid and
transient activation of both ERK and Akt, and that the
neuroprotective effect of BDNF in the experiments reported
above was observed after a 24 h incubation period, we
hypothesized that neuroprotection by BDNF could be due to
a change in transcription and/or translation. Since long (24 h)
incubations with transcription or translation inhibitors are toxic
to hippocampal neurons, we determined the effect of
anisomycin, an inhibitor of protein synthesis, on the protection
by BDNF, using 6 h pre-incubation with the neurotrophin.
Figure 10a shows that the maximal neuroprotection by BDNF
was already observed at this period of incubation. When
hippocampal neurons were pre-incubated with anisomycin,
together with BDNF, the neuroprotection by the neurotrophin
was completely blocked (Figure 10b). Control experiments
showed that 5 mM anisomycin fully inhibited the incorporation
of [32S]cysteine and [32S]methionine into proteins in cultured
hippocampal neurons (not shown). Also, incubation of the
cells with anisomycin (5 mM), during a period corresponding to
the total duration of the experiments, did not affect cell
viability, as determined by fluorescence microscopy, using the
fluorescent dye Hoechst 33342 (not shown). Our data indicate
that BDNF neuroprotective effect against glutamate toxicity is
mediated through a protein synthesis-dependent mechanism.
BDNF increases Bcl-2 protein levels in cultured
hippocampal neurons
The Bcl-2 family proteins are key players in modulating
neuronal survival and death.49 We hypothesized that the
protein synthesis-dependent neuroprotective effect of BDNF
could be due to a change in the abundance of an antiapoptotic
member of this family of proteins. Cells were treated with
BDNF, for 24 h, and Bcl-2, Bcl-xL, Bad and Bax protein levels
were analyzed in cultured hippocampal neurons by Western
blot. Our results indicate that BDNF significantly increased the
abundance of Bcl-2 (Figure 11) in hippocampal neurons
when compared to control cells (Po0.01), to about 124% of
the control. In contrast, Bax, Bcl-xL and Bad protein levels
were not altered under the same experimental conditions
(Figure 11). Taken together, our results suggest that Bcl-2
may mediate, to some extent, the long-term protective effects
provided by BDNF against glutamate toxicity.
Discussion
In this work, we have shown that pre-incubation with BDNF or
NT-3 protects cultured hippocampal neurons against gluta-
mate toxicity, by acting at the level or upstream of the
activation caspase-3-like enzymes. Neuroprotection by BDNF
was mediated through a transient activation of the Ras/MAPK
pathway and of the PI3-K/Akt pathway, which was detected by
the phosphorylation of its mediators ERK1/2 and Akt,
respectively. Blocking each of these pathways, with specific
pharmacological inhibitors or with dominant-negative con-
structs of MEK and Akt, prevented the neuroprotective effect
of BDNF. Our results also show that de novo protein synthesis
is required for neuroprotection by BDNF and, accordingly,
incubation of hippocampal neurons with the neurotrophin
increased Bcl-2 protein levels. The effects of BDNF and NT-3
observed in the present work are in agreement with the
reported presence of TrkB and TrkC receptors in the
hippocampus from early in development,50–52 in contrast
with the lack of TrkA receptors.26 Accordingly, pre-incubation
of hippocampal neurons with NGF did not affect glutamate
toxicity.
In ischemia and hypoxia, the massive release of glutamate
induces neuronal injury of the neuronal population in the
area of insult, but the mode of cell death (apoptosis
Figure 6 BDNF induces a transient activation of Akt in cultured hippocampal
neurons. Cellular preparations were treated with 100 ng/ml BDNF for the
indicated time periods and then lysed and analyzed by immunoblot against P-Akt
(Ser473) (a and b). The membranes were then stripped and reprobed against
P-Akt (Thr308) (a and c). Protein loading (12.5 mg protein) was checked by
stripping and reprobing the membrane with an anti-tubulin (a-tubulin) antibody.
Panel (a) shows the result of a representative experiment. In each experimental
condition the immunoreactivity obtained was calculated as a percentage of the
total signal obtained for P-Akt (Ser473) (b) or P-Akt (Thr308) (c). Data are
presented as mean7S.E.M. of four independent experiments
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versus necrosis) changes during development53 and depends
on the extent of the insult.54 In the present work, we showed
that BDNF promotes survival of cultured hippocampal
neurons under excitotoxic conditions, where cell death
occurs by apoptosis. Glutamate-induced cell death was
partially prevented by Z-DEVD-FMK, and the cleavage of
Ac-DEVD-pNA, a substrate of caspase-3-like enzymes, was
completely abrogated in extracts prepared from neurons
pre-treated with BDNF, for 24 h, before the excitotoxic
insult (Figure 2). The protective effect of BDNF observed in
this work, mediated by the activation of Trk receptors,
contrasts with the toxicity of neurotrophins in cultured
cerebrocortical55 and hippocampal neurons.56 In the latter
study, neurotrophins targeted mainly a subpopulation of
neurons that express p75 receptors and lack Trk neurotrophin
receptors. Since the majority of hippocampal neurons present
in the cultures used in this work express Trk receptors (not
shown), in agreement with previously reported results
showing that about 90% of cultured hippocampal neurons
express these receptors,52 this may account for the apparent
discrepancy between our findings and the results reported by
Friedman.56 This difference in the expression of Trk receptors
may be due to developmental changes in the abundance of
the receptors, since we have used 7–8 DIV cells and
neurotrophin toxicity was observed in five DIV neurons.
Differences in the composition of the culture medium may
Figure 7 The neuroprotective effect of BDNF is mediated through the PI3-K/Akt pathway. Hippocampal neurons were pretreated with the PI3-K inhibitors, LY294002
(30 mM) or wortmannin (100 nM), 15 min before they were incubated (a), or not (b), for 24 h, with 100 ng/ml BDNF. The cells were then challenged with glutamate and cell
death was accessed 7 h later by fluorescence microscopy, using the fluorescence dyes Syto-13 and PI. (c) Hippocampal neurons were pretreated with 30 mM LY294002
or 100 nM wortmannin, for 15 min, and then incubated with BDNF, for 7.5 min, with or without PI3-K inhibitors. Cells were lysed and total cell extracts were analyzed by
Western blot, using an anti-phospho-Akt (Ser473) antibody. Protein loading was checked by stripping and reprobing the membrane with an anti-tubulin (a-tubulin)
antibody. The data are representative of three independent experiments. In (d), hippocampal neurons were co-transfected with a dominant-negative construct of Akt
(Akt KN) and GFP (5 : 1), for 24 h, and then treated with 100 ng/ml BDNF, for 24 h. After incubation with BDNF the cells were challenged with 125 mM glutamate, for
20 min, and death of GFP-positive neurons was assessed 14 h later, by fluorescence microscopy, using the fluorescent dye Hoechst 33342. Data are presented as
mean7S.E.M. of the indicated number of experiments, performed in independent preparations, and are expressed as a percentage of cell death, by apoptosis,
observed in response to glutamate stimulation alone. Akt KN increased basal cell death by about 9%; subtraction of basal death and normalization to 100% cell death in
the glutamate treated-only condition overcame this problem. ***Po0.001 as compared to glutamate-induced cell death
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also explain the discrepancy in the effect of neurotrophins in
cultured hippocampal neurons.
The transient phosphorylation (activation) of ERK1/2 in
hippocampal neurons stimulated with BDNF, observed in the
present work, is in agreement with previous findings in the
same preparation,52 and with the relatively fast rate of
desensitization of TrkB receptors.57 A downregulation of TrkB
receptors under sustained exposure to BDNF may also
account for the transient phosphorylation (activation) of Akt,
which followed a kinetics similar to that observed for ERK1/2
phosphorylation. The main difference between the two path-
ways was that Akt phosphorylation was already significant
under resting conditions. This is in agreement with the
fundamental role played by Akt in neuronal survival (reviewed
by Downward15), although the kinase is probably not the only
target of the PI3-K-induced survival activity.58,59
The mechanism by which BDNF exerts its neuroprotective
role is still controversial, and may depend on the insult. We
have found that the pharmacological inhibitors of MEK,
Figure 8 Cross-talk between the PI3-K/Akt pathway and the Ras/MAPK
pathway. (a) Hippocampal neurons were pretreated with vehicle, 30 mM
LY294002 or 100 nM wortmannin, for 15 min, and then with 100 ng/ml BDNF,
for 7.5 min, with or without PI3-K inhibitors. In the control experiments the cells
were maintained in the absence of BDNF, without (control) or with inhibitors, for
the same period of time. Cells were lysed and total cell extracts were analyzed by
Western blot, using an anti-phospho-ERK1/2 antibody. (b) Hippocampal neurons
were pretreated with vehicle, 20 mM PD098059 or 300 nM U0126, for 15 min, and
then with 100 ng/ml BDNF, for 7.5 min, with or without MEK inhibitors. In the
control experiments the cells were maintained in the absence of BDNF, in culture
medium lacking (control) or containing the inhibitors, for the same period of time.
Cells were lysed and total cell extracts were analyzed by Western blot, using an
anti-phospho-Akt (Ser473) antibody. Protein loading was checked by stripping
and reprobing the membranes with an anti-tubulin (a-tubulin) antibody.
Quantification of the immunoreactivity is shown in the lower panels. Data are
representative of three independent experiments
Figure 9 BDNF does not prevent the glutamate-evoked activation of JNK and
p38 MAPK. Hippocampal neurons were incubated or not with 100 ng/ml BDNF,
for 24 h, and then challenged with glutamate (125 mM), for 5 min. Cells were then
lysed and analyzed by immunoblot against phospho-p38 (Thr180/Tyr182) (a),
and P-JNK (Thr183/Tyr185) (b). In (A) protein loading (30 mg) was checked by
stripping and reprobing the membrane with an anti-actin antibody. In (b), the lack
of change in immunoreactivity in the heavier bands was used as a loading
control. In each experimental condition the immunoreactivity obtained was
calculated as a percentage of the control. The immunoblots show representative
experiments. Data are presented as mean7S.E.M. of 3–4 different experiments,
performed in independent preparations. **Po0.01 and ***Po0.001 as
compared with control nonstimulated cells
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PD098059 and U0126, inhibited the neuroprotection provided
by BDNF against the glutamate toxicity, and similar results
were obtained using a dominant-negative form of MEK.
Similarly, LY294002 and Wortmannin, two distinct inhibitors
of PI3-K, abrogated BDNF protection of hippocampal neurons
and transfection experiments with a dominant-negative form
of Akt confirmed the pharmacological data. The participation
of the PI3-K pathway, together with the MEK/ERK pathway,
as a survival mechanism stimulated by BDNF in cultured
hippocampal neurons subjected to an excitotoxic insult
contrasts with the relative role of those signaling cascades
in neuroprotection in studies of neuronal injury from trophic
support withdrawal. Indeed, PI3-K was identified as the major
regulator of neurotrophin-mediated survival responses in
NGF-dependent PC12 cells,60 and in cerebellar,61 cortical,62
sympathetic,63–65 sensory66 and motor neurons.67 In contrast,
the MEK/ERK pathway does not contribute or plays a minor
role in NGF-dependent survival of PC12 cells68 and sensory
neurons,64,65 and in the BDNF-dependent survival of cere-
bellar granule neurons.34,69 This signaling pathway plays a
Figure 11 BDNF increases Bcl-2 protein levels in cultured hippocampal
neurons. Cultured hippocampal neurons were pretreated with 100 ng/ml BDNF,
for 24 h. Cells were then lysed and total cell extracts were analyzed by Western
blot, using antibodies against the indicated proteins of the Bcl-2 family. Protein
loading was checked by stripping and reprobing the membranes with an anti-
tubulin (a-tubulin) antibody. The lower panel shows the quantification of the
immunoreactivity obtained in the upper panel. Data are the average7S.E.M.
four independent experiments, performed in independent preparations. In BDNF-
treated cultures, the mean Bcl-2 immunoreactivity was 124.073.3% (n¼ 4) of
the control (**Po0.01, as determined using the Students t-test)
Figure 10 BDNF protects hippocampal neurons against glutamate toxicity
through a protein synthesis-dependent mechanism. (a) Cultured hippocampal
neurons were pretreated with 100 ng/ml BDNF for the indicated time periods and
then challenged with 125 mM glutamate, for 20 min. Cell death was assessed
14 h after the excitotoxic insult, by looking at nuclear morphology, using the
fluorescent dye Hoechst 33342. (b) Cultured hippocampal neurons were
pretreated with 5mM anisomycin, for 15 min, and then stimulated or not with
100 ng/ml BDNF, for 6 h. Cells were then challenged with glutamate, as indicated
above, and returned to conditioned medium without anisomycin, in the presence
or in the absence of BDNF, as indicated. Cell death was assessed by looking at
nuclear morphology, using the fluorescent dye Hoechst 33342. Data are
presented as mean7S.E.M. of the indicated number of experiments, performed
in independent preparations, and are expressed as a percentage of cell death, by
apoptosis, in response to glutamate stimulation alone. ***Po0.001 as compared
to glutamate-evoked cell death under control conditions. þ þ þPo0.001 as
compared to glutamate-induced cell death in the presence of BDNF
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major role in the protective effect of BDNF against DNA-
damaging agents in cerebrocortical neurons62 and against
in vivo hypoxic-ischemic brain injury.70 The Ras/ERK pathway
stimulated by NGF also inhibits apoptotic death of sympa-
thetic neurons subjected to cytosine arabinoside.65 These
findings suggest that the major role of MEK/ERK is to protect
neurons from death due to injury or toxicity. The fact that both
the MEK/ERK and the PI3-K contribute to the protection of
hippocampal neurons by BDNF from glutamate toxicity may
be explained by the activation of multiple lethal reactions
during excitotoxic cell death.71,72 After hypoxia-ischemia,
there is an increase in double-stained cells for p-ERK and
p-Akt in the ischemic penumbra (IP), where cells die mainly
by apoptosis, in contrast to the ischemic core (IC), which
suggests a cooperative role of both signals for survival in
the IP.73
The simultaneous contribution of the PI3-K and MEK/ERK
to the protection of hippocampal neurons by BDNF from
glutamate-evoked apoptotic death may also be due to the
cross-talk between the two pathways. Indeed, when the effect
of BDNF on ERK1/2 phosphorylation was assessed in the
presence of LY294002 or wortmannin, we observed a potent
decrease in the activation of the kinases. These results
indicate that the PI3-K/Akt pathway contributes to the
activation of the Ras/MAPK pathway, in agreement with a
recent report showing that PDK1 directly binds and activates
MEK, therefore contributing to the activation of this pathway.40
PI3-K is also responsible for maintaining constitutive ERK1/2
activity in different cell lines, where basal PI3-K and ERK
activities are required to prevent cell death.74 Other studies
have shown that the effect of PI3-K on the Ras/MAPK
pathway may occur both upstream of Ras and between Ras
and ERK2.41–44,75 In contrast, Akt phosphorylates Raf-1 on
Ser-259 and negatively controls its activity in MCF-7 cells
stimulated with high but not with low doses of mitogenic
stimuli, suggesting that the Raf-Akt cross-talk is regulated in a
concentration- and ligand-dependent manner.76 The cell type
and ligand specificities of the effects of PI3-K inhibitors on
MEK/ERK activity, and the fact that a similar inhibition was
observed in the present work with two chemically distinct
compounds, strongly suggest that this is a specific effect. The
differences observed in the cross-talk between the Ras/
MAPK and PI3-K/Akt pathways in distinct models could
therefore be due to differences in the type and dose of the
agonist and in the cellular background used.
In addition to the cross-talk between the Ras/MAPK and the
PI3-K pathways that may account for their role in neuropro-
tection by BDNF under excitotoxic conditions, the results are
also compatible with a role for a common mechanism acting
downstream of the two pathways. Accordingly, the Ras/MAPK
and the PI3-K pathways are known to stimulate the serum
response factor (SRF), which plays a role in neuronal
survival.77
Neurotrophins activate other transcription factors, which
can also upregulate the expression of several target genes.
Akt was also shown to inhhibit Forkhead transcription factors,
inhibiting their ability to induce the expression of death genes.
Furthermore, Akt may also induce the expression of survival
genes (Bcl-2, Bcl-xL, and several inhibitor of apoptosis
proteins), by activating cAMP response-element binding
protein (CREB) and nuclear factor-kB.15 BDNF also upregu-
lates the antioxidant defenses in cultured hippocampal
neurons by a still unknown mechanism.17 We showed that
anisomycin, a protein synthesis inhibitor, completely blocked
the neuroprotective effect of BDNF in cultured hippocampal
neurons. In agreement with the role of protein synthesis and
the Ras/MAPK and PI3-K signaling pathways in neuroprotec-
tion by BDNF reported here, chemical inhibitors of PI3-K and
MEK fully blocked protein synthesis induced by BDNF in
cultured cerebrocortical neurons.78
We also showed that upon treatment with 100 ng/ml BNDF,
for 24 h, Bcl-2 protein levels were increased when compared
to the control, suggesting that this protein may be, at least in
part, responsible for the protection by the neurotrophin. This is
in agreement with a previous report79 where NGF-mediated
survival of sympathetic neurons was shown to be mediated by
a mechanism requiring CREB family transcription factors and
Bcl-2 expression. Although the levels of the other Bcl-2 family
members tested, Bcl-xL, Bad and Bax, were not altered in
hippocampal neurons stimulated with BDNF for 24 h, we
cannot exclude the possibility that BDNF may have also
prevented the translocation from the cytoplasm to the
mitochondria of proapoptotic proteins, such as Bad, Bax and
Bak. Pre-incubation of hippocampal neurons with BDNF, for
24 h, did not affect glutamate-induced phosphorylation of JNK
and p38 MAPK. Therefore, although these stress-activated
kinases have been shown to contribute to apoptotic cell death,
by upregulating proapoptotic BH3-only Bcl-2 family members
(e.g., Whitfield et al.80), BDNF is unlikely to modulate this
death pathway under the experimental conditions used in this
work. Recent studies have shown that activation of TrkB
receptors elicits a complex program of changes in gene
expression,81 which will cause multiple changes in the
proteome. Therefore, in addition to Bcl-2, other proteins are
likely to contribute to neuroprotection by BDNF under
excitotoxic conditions.
Although neurotrophic factors protect CNS neurons from
excitotoxic injury, their clinical use is made difficult due to
several drawbacks that generally affect large polypeptides
applied as drugs. Therefore, there is currently an active
search for delivery strategies of neurotrophic factors and for
neurotrophic factor mimetics.82,83 A strategy that could be
envisaged is based on agents that selectively target the
signaling pathways that contribute to neuroprotection from the
excitotoxic injury. The results reported here suggest that
agents that selectively target the PI3-K and/or the MEK/ERK
pathways may be clinically useful in the protection of neurons
from glutamate toxicity.
Materials and Methods
Materials
Neurobasal medium, the B27 supplement, trypsin and the plasmid
maxiprep system were purchased from GIBCO Invitrogen (Paisley, UK).
Nerve growth factor (NGF) was obtained from Alomone (Jerusalem, Israel)
and BDNF and NT-3 were kind gifts of Regeneron (Tarrytown, NY, USA).
Syto-13 and PI were from Molecular Probes (Leiden, The Netherlands).
The anti-active MAPK antibody was from Promega (Madison, WI,
USA) and the anti-phospho-Akt (Ser473), anti-phospho-Akt (Thr 308),
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anti-phospho-p38 MAPK, anti-phospho-JNK, anti-Bcl-xL, anti-Bad and
anti-Bax antibodies were from Cell Signaling Technology (Beverly, MA,
USA). The rabbit monoclonal anti-ERK1/2 antibody (MK12) was from BD
Biosciences (San Jose, CA, USA). The anti-Bcl-2 and the anti-a-tubulin
antibodies were from Zymed (San Francisco, CA, USA), and the mouse
anti-actin antibody was from Chemicon (Temecula, CA, USA). The rabbit
anti-phospho-TrkA (phosphotyrosine 490) antibody was from Sigma
Chemical Co. (St. Louis, MO, USA). LY294002, wortmannin, PD098 059
and U0126 were purchased from Calbiochem (La Jolla, CA, USA), Ac-
DEVD-pNA was from Bachem (Bubendorf, Switzerland) and Z-DEVD-
FMK from Enzyme Systems Products (Livermore, CA, USA). Reagents
used in immunoblotting experiments were purchased from Bio-Rad
(Hercules, CA, USA), with the exception of the polyvinylidene difluoride
(PVDF) membranes, the alkaline phosphatase-linked anti-mouse and
anti-rabbit secondary antibodies, and the enhanced chemifluorescence
(ECF) reagent, which were obtained from Amersham Biosciences
(Buckinghamshire, England). All other reagents were from Sigmal
Chemical Co. or from Merck KGaA (Darmstadt, Germany). MEK KN
and Akt KN were generously provided by Michael Greenberg (Harvard
Medical School and Children’s Hospital, Boston, USA).
Preparation and culture of hippocampal neurons
Primary cultures of rat hippocampal neurons were prepared from the
hippocampi of E18-E19 Wistar rat embryos, after treatment with trypsin
(0.5 mg/ml, 15 min, 371C) and deoxyribonuclease I (0.20 mg/ml), in Ca2þ -
and Mg2þ -free Hank’s balanced salt solution (HBSS; 137 mM NaCl,
5.36 mM KCl, 0.44 mM KH2PO4, 0.34 mM Na2HPO4  2H2O, 4.16 mM
NaHCO3, 5 mM glucose, supplemented with 0.001% phenol red, 1 mM
sodium pyruvate and 10 mM HEPES, pH 7.4).84 The hippocampi were
then washed in HBSS supplemented with 10% FCS in order to stop trypsin
activity and, after centrifugation at 140 gav, for 1 min, the cells were
mechanically dissociated in HBSS. Hippocampal cultures were maintained
in serum-free Neurobasal medium, supplemented with B27 supplement,
glutamate (25 mM), glutamine (0.5 mM) and gentamicin (0.12 mg/ml). The
cells were kept at 371C in a humidified incubator of 5% CO2/95% air, for
7–8 days, the time required for maturation of hippocampal neurons. The
glial content of hippocampal cultures maintained in Neurobasal medium,
supplemented with B27 supplement, was estimated to be about 0.5% of
the total cell population.85
Cell viability experiments
The cells were cultured for 7 days, on poly-D-lysine-coated glass
coverslips, at a density of 45 103 cells/cm2, before pre-incubation, for
24 h, in the presence or in the absence of neurotrophins, added to the
culture medium. The neurotrophin stock solutions were prepared in sterile
phosphate-buffered saline (PBS). The cells were then incubated with
125 mM glutamate in supplemented Neurobasal medium, for 15 min at
371C, in a humidified incubator. After stimulation with glutamate, the cells
were further incubated with the original culture medium, containing or
not neurotrophins, for 7 h at 371C. Cell viability was then measured by
staining with the fluorescent dyes Syto-13 (1.2 mM) and propidium iodide
(2.9 mg/ml), in Naþ medium (in mM: 140 mM, 5 KCl, 1 CaCl2, 1 MgCl2, 5.5
glucose, 20 HEPES and 1 NaH2PO4, pH 7.4), for 2–3 min at room
temperature. Syto-13 is membrane permeant and stains DNA and RNA of
cells with intact plasma membranes. PI is membrane impermeant and
stains the nuclei of cells with disrupted plasma membranes.18 Cells were
visualized on a Nikon Diaphot-TMD fluorescence microscope, using the
OMEGAt three-dye filter set XF 63. In the experiments where the effect of
MEK inhibitors or PI-3 inhibitors was investigated, the compounds were
added to the culture medium 15 min before stimulation with BDNF.
Alternatively, the cells were incubated with 125 mM glutamate in
supplemented Neurobasal medium, for 20 min at 371C, in a humidified
incubator. After stimulation with glutamate, the cells were further
incubated with the original culture medium, containing or not neuro-
trophins, for 14 h at 371C. Cell viability was then measured by fixing the
cells in 4% paraformaldehyde, for 15 min at room temperature. Fixed
cells were washed and stained with the fluorescent dye Hoechst 33342
(0.5 mg/ml). The coverslips were mounted on glass slides and examined
under a Zeiss Axiovert 200 fluorescence microscope.
Measurement of caspase-3-like activity
The cells were cultured for 7 days, on poly-D-lysine-coated 24-well cluster
plates, at a density of 0.2 106 cells/cm2, before pre-incubation, for 24 h,
in the presence or in the absence of BDNF, added to the culture medium.
The cells were then incubated with 125 mM glutamate in supplemented
Neurobasal medium, for 15 min at 371C, in a humidified incubator. In
control experiments the cells were incubated in glutamate-free
supplemented Neurobasal medium, for the same time period. After
stimulation with glutamate, the cells were further incubated with the
original culture medium, containing or not BDNF, for 5 h at 371C. The cells
were then washed twice with KPM (in mM: 50 KCl, 50 PIPES, 10 EGTA
and 2 MgCl2, pH 7.0), and once with KPM supplemented with CLAP
(chymostatin, leupeptin, antipain and pepstatin A, at 1 mg/ml), phenyl-
methylsulfonyl fluoride (PMSF) (100mM) and dithiothreitol (DTT) (1 mM).
The extracts were prepared in the same medium, supplemented with 0.5%
Triton X-100, and the protein content was determined by the Bio-Rad
method. Caspase-3-like activity was measured at 371C, in microtiter
plates, with a DEVD-pNA concentration of 100mM and a total protein
concentration of 150 mg/ml. The cleavage of the substrate was measured
every 15 min, at 405 nm, using a microtiter plate reader (SLT Spectra,
Salzburg, Austria).
Immunoblotting
The cells were cultured for 7 days, on poly-D-lysine-coated four-well
(200 103 cells/cm2, for the time-course experiments) or six-well
(90 103 cells/cm2, for the experiments with the inhibitors) cluster plates,
before pre-incubation in the presence or in the absence of BDNF. When
the effect of inhibitors was tested, the cells were pre-incubated with the
compounds for 15 min before stimulation with the neurotrophin. The cell
extracts were prepared as indicated in the previous section, with the
exception that KPM was supplemented with 50 mM sodium fluoride and
1.5 mM sodium orthovanadate. The samples were diluted with a 2
concentrated sample buffer (100 mM Tris, 100 mM glyine, 4% SDS, 8%
b-mercaptoethanol, 8 M urea and 1.5 mM sodium orthovanadate), and
equal amounts of protein, as determined by the Bio-Rad method, were
then separated by electrophoresis on 12% SDS-polyacrylamide gels
(SDS-PAGE) (or 7.5% gels when pTrk receptors were detected). The
proteins were transferred electrophoretically to PVDF membranes, which
were then blocked for 1 h at room temperature, in Tris-buffered saline
(137 mM NaCl, 20 mM Tris-HCl, pH 7.6) containing 0.1% Tween 20 (TBS-
T) and 5% low-fat milk. The membranes were incubated overnight at 41C
(or 1 h at room temperature), with rabbit anti-active MAPK (1 : 3500), anti-
phospho-Akt (Ser473) (1 : 5000), anti-phospho-Akt (Thr 308) (1 : 5000),
anti-phospho-p38 MAPK (1 : 1000) or anti-phospho-JNK (1 : 1000) anti-
bodies, or with a mouse anti-ERK (pan) antibody (1 : 5000), diluted in TBS-
T containing 1% low-fat milk. Incubation with the anti-phospho-TrkA
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(phosphotyrosine 490) (1 : 500) antibody was performed in TBS-T with 1%
BSA for the same period of time. After extensive washing with TBS-T,
membranes were incubated with the alkaline phosphatase-linked anti-
rabbit or anti-mouse sera, diluted 1 : 20 000 in TBS-T with 1% low-fat milk,
for 1 h at room temperature. Protein immunoreactive bands were
visualized by enhanced chemifluorescence (ECF) on a Storm 860 Gel
and Blot Imaging System (Amersham Biosciences), following incubation of
the membranes with ECF reagent for 5 min. Where indicated, the
membranes were stripped and reprobed with mouse anti-a-tubulin
(1 : 1000) or anti-actin (1 : 1000) antibodies.
Immunoblotting experiments for detection of Bcl-2 family members were
performed as described above, with slight modifications. The samples were
diluted with a 2 concentrated sample buffer (125 mM Tris, pH 6.8, 100 mM
glycine, 4% SDS, 200 mM DTT, 20% glycerol and 0.01% bromophenol blue)
and the membranes were incubated with rabbit anti-Bcl-xL (1 : 1000), anti-
Bax (1 : 1000) or anti-Bad (1 : 1000) rabbit antibodies, or with a mouse anti-
Bcl-2 (1 : 500) antibody. Where indicated, the membranes were stripped and
reprobed with a mouse anti-a-tubulin antibody (1 : 1000).
Transfection experiments
Hippocampal neurons were transiently transfected at DIV4 using a calcium
phosphate co-precipitation protocol.34 Cells at a density of 45 103 cells/
cm2 were washed twice with DMEM and then incubated with 250 ml of
fresh DMEM, for 45 min, in a humidified incubator with 5% CO2 at 371C.
During this period of time, the DNA/calcium phosphate precipitate was
prepared by mixing one volume of DNA in 250 mM CaCl2 with an equal
volume of 2HBS solution (274 mM NaCl, 10 mM KCl, 1.4 mM
Na2HPO4, 15 mM D-glucose, 42 mM HEPES, pH 7.06). For each well of
a 24 multiwell plate, the amount of DNA used was 2 mg for MEK KN or Akt
KN, and 0.4 mg for GFP. In the experiments where GFP toxicity was tested
alone, 1 mg of GFP DNA was used. The precipitate was let to form for
20 min at room temperature and then added to cells, which were returned
to the incubator for another 20 min. The cells were then washed three
times with BME supplemented with 10% FCS, to stop transfection, and
returned to the incubator for another hour. Neurons were then washed
twice with plain DMEM and the conditioned medium was added back.
Experimental treatments started 24 h after transfection.
Statistical analysis
Results are presented as means7S.E.M. of the indicated number of
experiments, performed in independent preparations. All the results were
analyzed using one-way ANOVA, followed by Newman–Keuls multiple
comparison test except in Figure 11, where Student’s t-test was used.
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